O afea e maua ai se tui COVID-19? Faʻafefea ona togafitia se tasi faasaga i Coronavirus? E i ai se vailaʻau faʻasaga i coronavirus? O fesili lauiloa ia e le gata ile Google Search coronavirus.

Fai mai le saienitisi, ave tatau ona faʻamoemoe e faʻaalu le 12 i le 18 masina, ae fai mai isi saienitisi e vave lava ona maua togafitiga, fai mai saienitisi.

E ui o le tui e faasaga i le tala o le coronavirus e faʻamoemoe e alu i luga le tausaga e atiaʻe ma suʻesuʻe ai, o isi togafitiga mo le taufaʻamataʻu mataʻutia e mafai ona na o ni nai masina le mamao, fai mai tagata popoto o le soifua maloloina.

E silia i le 417,721 tagata ua maua ile COVID-19 ma ua ova 18,605 ua maliliu. E tele atunuʻu ua oʻo i le lokaina ona o le numera o i latou na aafia i le faʻamaʻi pepesi tele o loʻo faʻaauau pea ona siisii i luga.

Saienitisi i le salafa o le lalolagi o loʻo tamoʻe e atiaʻe togafitiga ma tui, lea e tatau ona faia i le tele o taamilosaga o suʻega ma faʻataʻitaʻiga faʻataʻitaʻiga ae le i see atu i vaega tele.

"E ova atu i le 20 tui o loʻo faia i le lalolagi atoa, ma e tele togafitiga o loʻo i totonu o faʻataʻitaʻiina faʻafitauli," o le saunoaga lea a le sooupu a le World Health Organization i le Media Line. “E leai se togafitiga ma se vailaʻau o iai, ae o tagata suʻesuʻe i le salafa o le lalolagi [o loo galulue] malosi mo ia.”

E ui o le tui e ono faia i le va o le 12 ma le 18 masina e faʻamaonia le saogalemu ma aoga ma gaosia mo le faʻaaogaina tele, o isi togafitiga lelei e ono aliaʻe vave.

O le polofesa o Peter Jay Hotez, o le virologist lauiloa ma o le pule o le Baylor College of Medicine's National School of Tropical Medicine i Houston, Texas, na ia taua i le Media Line e faapea, o le muamua togafitiga e mafai ona galue faasaga i le COVID-19 o le a avea ma ituaiga o vailaʻau o le tino. , lea e tui atu ai le vailaʻau o le tagata ua toe malosi mai le siama i se tagata maʻi.

I totonu o se suʻesuʻega na lomia i totonu le Tusi o talafaamaʻi pipisi i le 2014, na faʻataʻitaʻia e le au suʻesuʻe le ono aoga o le faʻamalosiina o le toto toto e faʻaititia ai le tulaga o le oti peʻa faʻatautaia ia i latou na maua i le faʻamaʻi ogaoga o faʻamaʻi manava (SARI) i le taimi lava na aliaʻe ai a latou faʻailoga.

E tusa ai ma le faamatalaga a Hotez, o le isi togafitiga e aliaʻe mai pe a maeʻa lenei, e foliga mai o le "toefaʻaleleia o vailaʻau antiviral o loʻo i ai i ni nai vaiaso poʻo masina, ona maua ai lea o vailaʻau vailaʻau fou i totonu o le tausaga, ma tui i le tasi i le tolu tausaga."

O le mea e malie ai, o Hotez ma lana 'au saienitisi ua uma ona faia se tui puipuia o le coronavirus i tausaga ua mavae, ina ua maeʻa le 2002-2004 SARS faʻamaʻi, lea na salalau atu i fafo o Saina ma iʻu ai na fasiotia le sili atu i le 770 tagata i le lalolagi atoa. Peitaʻi, ina ua oʻo le tui i le tulaga o suʻega o tagata i le 2016, na le mafai ai ona toe maua se isi tupe ma e leʻi maeʻa lava faʻamasinoga.

"I le taimi na matou gaosia ai, sa le toe fiafia tagata i faʻamaʻi o le coronavirus ma faʻamaʻi pipisi," o le tala lea a Hotez, ma ua faʻapea mai, o loʻo galulue nei tagata suʻesuʻe e toefaʻaleleia lena tui mo le COVID-19.

Coronaviruses o se vaega o fesoʻotaʻiga faʻamaʻi e mafua ai faʻamaʻi e aofia ai nisi tulaga o le masani malulu, ae le naʻo SARS ma COVID-19.

Dr. Rivka Abulafia-Lapid, o se tagata aʻoaʻo matua i virology i le Iunivesite Eperu o Ierusalema, na malilie ma Hotez o antiviral togafitiga e ono maua i totonu o le ono masina ma sili atu vave nai lo se tui, faʻatapulaʻaina soʻo se atinaʻe le fuafuaina.

"Ua i ai ia Isaraelu ni vailaʻau eseʻese e 11 mo faʻataʻitaʻiga [i COVID-19 tagata mamaʻi]… o lea ou te fai atu ai o le mea muamua lava e sau i fafo o se vailaʻau e masani ona malilie i ai saienitisi o le lalolagi ma le FDA [le US Food and Fualaʻau Faʻasaina o Fualaʻau], sosoʻo ai ma le vailaʻau puipui, "Abulafia-Lapid told The Media Line. "I ni nai masina, o le a latou o mai ai ma se togafiti i le lumanaʻi pe atonu o se inuina o fualaʻau."

Abulafia-Lapid, o le sa faauluuluina le vaega suesue i Isaraelu mo le 25 tausaga, i le fausiaina o se tui talafeagai e tetee atu ai i le HIV ma isi faamai o le autoimmune, fai mai o soʻo se tui e tatau ona faia se taimi umi o suʻega taimi e aofia ai le tele o vaega o faʻataʻitaʻi faʻafomaʻi.

Faʻatasi ai ma vailaʻau o loʻo i ai nei o loʻo vaʻaia o ni sui tauva anti-coronavirus i le taimi lea, na ia faʻasino atu i le kamupani faʻatonu o le biotech i Kalefonia o loʻo faʻataʻitaʻia le faʻataʻitaʻiga o vailaʻau faʻafomaʻi o le antivirus a Kalefonia - na muamua suʻesuʻeina i tagata ma le Ebola virus - o se tagata muamua i luma i le faʻaaliga folafolaga Remdesivir ua uma ona faʻaaogaina i le tele o coronavirus-fesoʻotaʻi falemaʻi faʻataʻitaʻi.

I le taimi nei, na faasilasila mai ai e le lapoʻa o vailaʻau i Isalaelu, Teva, o le a foai atu le sili atu ma le 6 miliona inumaga o vailaʻau o le hydroxychloroquine sulfate i falemaʻi i le salafa o le Iunaite Setete mo nisi suʻesuʻega. O le vailaʻau, e masani ona faʻaaoga e togafitia ai le mumu, o loʻo suʻesuʻeina o se sui tauva e teteʻe ile COVID-19.

E tusa ai ma le ono maua o se togafitiga o le vailaau mo le puipuia o le tino, lea na taʻua e Hotez ua mafai ona faia i tagata mamaʻi, na faailoa mai e Abulafia-Lapid, e ui lava o se togafitiga e mafai ona faasaoina ai ola, ae o loʻo tumau pea luitau taua i le faʻateleina o lenei metotia mo le faitau afe o tagata.

Ae o le iuga lava, e ui i lea, e "matua talitonu lava o ia" o le lalolagi e ono masina le mamao mai se togafitiga lelei.

"I le lumanaʻi, e tatau ona tatou o mai i fafo i tausaga uma ma se fou [COVID-19] tui ona e suia pei o fulū," Abulafia-Lapid fai mai, ma faaopoopo mai talu ai o le siama e matua fou, o le tagata puipuiga o le tino o le taimi nei puipuia. tetee i ai "E tatau ona e aʻoaʻo le tino [pe faʻafefea ona puipuia faasaga i ai]," o lana tala lea.

puna: O le Medialine

OA MEA E AVEA MAI LENEI TUSI:

Peter Jay Hotez, a prominent virologist and the dean of the Baylor College of Medicine's National School of Tropical Medicine in Houston, Texas, told The Media Line that the earliest treatment that could work against COVID-19 would be a convalescent serum antibody therapy, in which the antibodies of a person who has recovered from the virus are injected into a sick patient.
“Israel already has 11 different drugs for trial [on COVID-19 patients] … so I would say that the first thing to come out will be a drug that will be commonly agreed upon by the world's scientists and the FDA [the US Food and Drug Administration], followed by a vaccine,” Abulafia-Lapid told The Media Line.
According to Hotez, the next treatment to emerge after this will most likely be “repurposed existing antiviral drugs in a few weeks or months, then new chemical drugs within a year, and a vaccine in one to three years.